| Olawunmi Aabiodun Lawal, MD | |
|
815 1st Ave Se, Suite 104, Aberdeen, SD 57401-4602 | |
| (605) 622-5458 | |
| (605) 622-5473 |
| Full Name | Olawunmi Aabiodun Lawal |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 815 1st Ave Se, Aberdeen, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386991412 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 9207 (South Dakota) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Healing Hands Healthcare Llc | Wichita falls, TX | Home health agency |
| Angels Care Home Health | Wichita falls, TX | Home health agency |
| Encompass Home Health Of Wichita Falls | Wichita falls, TX | Home health agency |
| Falls Home Health Services Inc | Wichita falls, TX | Home health agency |
| 1st Texas Home Health | Wichita falls, TX | Home health agency |
| Hospice Of Wichita Falls | Wichita falls, TX | Hospice |
| United Regional Health Care System | Wichita falls, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| United Regional Physician Group | 2163417478 | 95 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Cancer is growing by the day worldwide and the cancer cells still manage to evade both the body's defenses and medical intervention. Now an explanation to the phenomenon is provided by an Arizona State University scientist.
Bacteria are among the simplest organisms in nature, but many of them can still talk to each other, using a chemical "language" that is critical to the process of infection. Sending and receiving chemical signals allows bacteria to mind their own business when they are scarce and vulnerable, and then mount an attack after they become numerous enough to overwhelm the host's immune system.
Global nanotechnology company pSivida Limited, is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a new Australian patent for BioSiliconTM.
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.
› Verified 5 days ago
| Entity Name | United Regional Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407890775 PECOS PAC ID: 2163417478 Enrollment ID: O20040416001015 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Cancer is growing by the day worldwide and the cancer cells still manage to evade both the body's defenses and medical intervention. Now an explanation to the phenomenon is provided by an Arizona State University scientist.
Bacteria are among the simplest organisms in nature, but many of them can still talk to each other, using a chemical "language" that is critical to the process of infection. Sending and receiving chemical signals allows bacteria to mind their own business when they are scarce and vulnerable, and then mount an attack after they become numerous enough to overwhelm the host's immune system.
Global nanotechnology company pSivida Limited, is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a new Australian patent for BioSiliconTM.
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Olawunmi Aabiodun Lawal, MD Po Box 1460, Aberdeen, SD 57402-1460 Ph: (605) 622-5458 | Olawunmi Aabiodun Lawal, MD 815 1st Ave Se, Suite 104, Aberdeen, SD 57401-4602 Ph: (605) 622-5458 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Cancer is growing by the day worldwide and the cancer cells still manage to evade both the body's defenses and medical intervention. Now an explanation to the phenomenon is provided by an Arizona State University scientist.
Bacteria are among the simplest organisms in nature, but many of them can still talk to each other, using a chemical "language" that is critical to the process of infection. Sending and receiving chemical signals allows bacteria to mind their own business when they are scarce and vulnerable, and then mount an attack after they become numerous enough to overwhelm the host's immune system.
Global nanotechnology company pSivida Limited, is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a new Australian patent for BioSiliconTM.
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.
› Verified 5 days ago
Arlin Monroe Myrmoe, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 815 1st Ave Se, Suite E104, Aberdeen, SD 57401 Phone: 605-622-5458 Fax: 605-622-5473 | |
Dr. John Robert Fritz, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1228 18th Ave Ne, Aberdeen, SD 57401 Phone: 605-229-5323 | |
Dr. Racheal Tushabe, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 815 1st Ave Se Ste 104, Aberdeen, SD 57401 Phone: 605-622-5458 Fax: 605-622-5473 | |
Joan Harriott, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 3015 3rd Ave Se, Aberdeen, SD 57401 Phone: 605-725-1700 Fax: 605-725-1761 | |
Ronald Douglas Rovang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 815 1st Ave Se, Suite 104, Aberdeen, SD 57401 Phone: 605-622-5458 Fax: 605-622-5473 | |
Timothy Roy Waterman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 815 1st Ave Se, Suite 104, Aberdeen, SD 57401 Phone: 605-622-5458 Fax: 605-622-5473 |